Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for resectable colorectal peritoneal metastases: a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).

Status

Not yet recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518570-13-00

Enrollment

358

Registered

2024-11-12

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resectable peritoneal metastases of a colorectal origin

Brief summary

To determine the difference between both treatments in terms of overall survival (calculated from the interval from diagnosis of peritoneal metastases until death or last follow-up).

Interventions

DRUGAvastin 25 mg/ml concentrate for solution for infusion.

DRUGLeucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion

DRUGOxaliplatin Eugia 5 mg/ml concentraat voor oplossing voor infusie

DRUGXeloda 150 mg film-coated tablets

DRUG5-Fluorouracil Sandoz 50 mg/ml koncentrátum oldatos infúzióhoz

DRUGIRINOTECAN MYLAN GENERICS 20 mg/ml concentrato per soluzione per infusione

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To determine the difference between both treatments in terms of overall survival (calculated from the interval from diagnosis of peritoneal metastases until death or last follow-up).	—

Countries

Belgium, Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026